Posted from: Monday, April 08, 2019 - 04:29 PM - Present

Ranexa Generic Launched

February 27, 2019 – Lupin Pharmaceuticals has announced the launch of its generic for Gilead’s Ranexa® (ranolazine). Both products are U.S. FDA-approved to treat chronic angina (chest pain related to heart disease).

The launch follows a settlement agreement between Lupin and Genentech. Lupin’s generic will be available in both 500mg and 1,000mg dosage strengths. Recommended dosing is based on clinical symptoms, and ranges from 500mg twice daily to 1,000mg twice daily.

 

Last Updated Saturday, June 15, 2019 - 07:46 AM.